Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 1
2014 1
2015 2
2016 3
2017 4
2018 3
2019 3
2020 2
2021 3
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. Li Z, et al. Among authors: priedigkeit nm. Nat Commun. 2022 Apr 19;13(1):2011. doi: 10.1038/s41467-022-29498-9. Nat Commun. 2022. PMID: 35440136 Free PMC article.
Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine.
Ding K, Chen F, Priedigkeit N, Brown DD, Weiss K, Watters R, Levine KM, Heim T, Li W, Hooda J, Lucas PC, Atkinson JM, Oesterreich S, Lee AV. Ding K, et al. Among authors: priedigkeit n. Ann Oncol. 2022 Oct;33(10):1085-1088. doi: 10.1016/j.annonc.2022.06.005. Epub 2022 Jun 25. Ann Oncol. 2022. PMID: 35764274 Free PMC article. No abstract available.
HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, Nakhlis F, Bellon JR, Parker T, Strauss S, Jin Q, King TA, Overmoyer BA, Curigliano G, Regan MM, Tolaney SM, Lynce F. Tarantino P, et al. Among authors: priedigkeit n. Eur J Cancer. 2022 Oct;174:277-286. doi: 10.1016/j.ejca.2022.07.001. Eur J Cancer. 2022. PMID: 36116830
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Li Z, et al. Among authors: priedigkeit nm. Cancer Res. 2022 Apr 1;82(7):1321-1339. doi: 10.1158/0008-5472.CAN-21-2576. Cancer Res. 2022. PMID: 35078818 Free PMC article.
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, Boisen MM, Bhargava R, Weiss KR, Karsten MM, Denkert C, Blohmer JU, Leone JP, Hamilton RL, Brufsky AM, Elishaev E, Lucas PC, Lee AV, Oesterreich S. Basudan A, et al. Among authors: priedigkeit n. Mol Cancer Res. 2019 Feb;17(2):457-468. doi: 10.1158/1541-7786.MCR-18-0946. Epub 2018 Oct 24. Mol Cancer Res. 2019. PMID: 30355675 Free PMC article.
ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.
Charmsaz S, Doherty B, Cocchiglia S, Varešlija D, Marino A, Cosgrove N, Marques R, Priedigkeit N, Purcell S, Bane F, Bolger J, Byrne C, O'Halloran PJ, Brett F, Sheehan K, Brennan K, Hopkins AM, Keelan S, Jagust P, Madden S, Martinelli C, Battaglini M, Oesterreich S, Lee AV, Ciofani G, Hill ADK, Young LS. Charmsaz S, et al. Among authors: priedigkeit n. BMC Med. 2020 Nov 19;18(1):349. doi: 10.1186/s12916-020-01806-4. BMC Med. 2020. PMID: 33208158 Free PMC article.
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV. Hartmaier RJ, et al. Among authors: priedigkeit n. Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025. Ann Oncol. 2018. PMID: 29360925 Free PMC article.
24 results